Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Salmeterol pharmacokinetics following a 50-mcg dose by dry powder oral inhalation to healthy volunteers Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012
Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2 -adrenoreceptor agonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
In vivo blockade of CTLA-4 counteracts inhalation tolerance and leads to development of allergic airway inflammation in mice repeatedly exposed to aerosolized ovalbumin Source: Eur Respir J 2004; 24: Suppl. 48, 6s Year: 2004
Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Pharmacokinetics of selective PI3Kδ inhibitors after intratracheal instillation in mice Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
Lack of tolerance to the bronchoprotective effect with intermittent administration of salmeterol Source: Eur Respir J 2006; 28: Suppl. 50, 710s Year: 2006
Effects of intratracheal pf-00610355, an inhaled β2 adrenoceptor agonist, in anaesthetised animals Source: Annual Congress 2009 - New bronchodilators Year: 2009
Comparison of response to lipopolysaccharide administered by intravenous, orotracheal and inhaled routes in rats Source: Eur Respir J 2007; 30: Suppl. 51, 135s Year: 2007
The role of salbutamol inhalation in premedication of fiberopticbronchoscopy Source: Eur Respir J 2003; 22: Suppl. 45, 58s Year: 2003
Intermittent administration of salmeterol does not induce tolerance to the bronchoprotective effect in exercise induced bronchoconstriction Source: Eur Respir J 2003; 22: Suppl. 45, 497s Year: 2003
Dissociated systemic tolerance induced by repeated low doses of inhaled endotoxins in healthy humans Source: Eur Respir J 2003; 22: Suppl. 45, 378s Year: 2003
Rising single-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CSCR2, in healthy volunteers Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007
Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro Source: Eur Respir J 2002; 20: Suppl. 38, 91s Year: 2002
Rising multiple-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CXCR2, in healthy smokers Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007
Inhibition of the inhaled allergen challenge response by the CRTH2 antagonist OC000459 in patients with asthma Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010
Pharmacokinetics of 14 C-ciclesonide after oral and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 109s Year: 2002
Once-daily administration of indacaterol does not induce tachyphylaxis in vivo Source: Eur Respir J 2005; 26: Suppl. 49, 216s Year: 2005
Effect of an inhaled adenosine A2A agonist on the allergen induced late asthmatic response Source: Eur Respir J 2003; 22: Suppl. 45, 204s Year: 2003
Toxicity and safety of dextromethorphan inhalation in a mouse model prior its use in humans Source: Annual Congress 2011 - Translational models of disease Year: 2011